U.S. approves Shire’s drug for Gaucher disease
WASHINGTON, Feb 26 (Reuters) – The U.S. Food and Drug Administration approved Shire Plc’s (SHP.L) (SHPGY.O) Vpriv drug on Friday to treat children and adults with the most common form of Gaucher disease.
The injectable drug, which treats patients with Type 1 Gaucher disease, will serve as an alternative to Genzyme’s (GENZ.O) Cerezyme, which is in short supply due to manufacturing problems.
“Patients who previously received Cerezyme as an enzyme replacement therapy for their Type 1 Gaucher disease can be safely switched to Vpriv,” Julie Beitz, head of the FDA office that reviewed the drug, said.
(more…)
1 March | Gaucher Disease | No comment